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54% and Germany 45%). An overall increase in co-prescribing of clopidogrel and 
PPIs was observed in all countries from April 2006 to April 2009 except for France 
where omeprazole co-prescribing decreased in 2008–2009. The most frequently pre-
scribed PPI in combination with clopidogrel was omeprazole in all three countries 
(58% in the UK, 36% in France and 65% in Germany) The second most frequently 
used PPI was lansoprazole in the UK (36%), pantoprazole in Germany (21%) and 
esomeprazole in France (28%). The proportion of clopidogrel patients who were 
co-prescribed lansoprazole was 36% in the UK and only 11% in France and 2% in 
Germany. CONCLUSIONS: Overall prescribing of PPIs with clopidogrel after ACS 
is common in the UK, France and Germany. Since the publication of the OCLA study 
in 2008 no decrease in concurrent prescribing of clopidogrel and omeprazole was 
observed except in France. Revisions of national guidelines and the clopidogrel label 
in 2009 may further affect prescribing of PPIs, and especially omeprazole, with clopi-
dogrel in the future.
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OBJECTIVES: A previous study indicated that increasing nurse stafﬁ ng levels in 
Belgian general cardiac postoperative nursing units was associated with lower mortal-
ity rates. The aim of this study is to conduct a cost-effectiveness analysis of increasing 
nurse stafﬁ ng levels to the level of the 75th percentile in Belgian general cardiac post-
operative nursing units from a hospital perspective. METHODS: The intervention was 
an increase in the number of nursing hours per patient day to the 75th percentile for 
nursing units staffed below that level. The comparator was a “do nothing” alternative. 
Data on nurse stafﬁ ng levels were extracted from the Belgian Nursing Minimum Data 
set and data on in-hospital mortality from the Belgian Hospital Discharge Database. 
The number of life-years gained was calculated by multiplying the number of avoided 
deaths by the life expectancy of patients having a coronary artery bypass graft and 
patients having heart valve procedures. To this effect, survival rates were derived from 
the literature. National cost estimates for the year 2007 were used. Results were 
expressed in the form of the additional costs per avoided death and the additional 
costs per life-year gained. RESULTS: The costs of increasing nurse stafﬁ ng levels to 
the 75th percentile in Belgian general cardiac postoperative nursing units amounted to 
c1,211,022. Such nurse stafﬁ ng levels would avoid an estimated number of 45.9 (95% 
CI: 22.0–69.4) patient deaths per year and generate 458.86 (95% CI: 219.93–693.79) 
life-years gained annually. This corresponds with incremental cost-effectiveness ratios 
of c26,372 per avoided death and c2,639 per life-year gained. Sensitivity analyses 
indicated that the incremental cost-effectiveness ratio was robust to changes in input 
parameters. CONCLUSIONS: Increasing nurse stafﬁ ng levels appears to be a cost-
effective intervention as compared to other cardiovascular interventions.
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OBJECTIVES: Health services research is an expanding ﬁ eld of interest for recently 
introduced medical technologies. Complementing efﬁ cacy results with effectiveness 
data illustrates the clinical contribution of a new technology in the real-life setting. 
With effectiveness results being relatively stable over time, the change in reimburse-
ment and price decreases have a substantial impact on initial cost-effectiveness con-
siderations. The three-year GERSHWIN study (GERman Stent Health outcomes 
WIthin Normal practice) was designed to determine long-term clinical outcome and 
economic consequences of Sirolimus-eluting stents (SES) versus bare-metal stents BMS 
in the treatment of CAD from a societal prospective. Economic analysis resulted in 
an ICER of c29,868 per avoided major adverse coronary events (MACE) based on 
2003 to 2005 prices. Due to substantial price reductions, a remodelling with current 
prices would increase applicability of results by decision-makers. METHODS: Com-
plete intention-to-treat study data were valued and analyzed with 2009 prices for the 
main cost drivers (hospital case rate, incremental stent cost and generic clopidogrel 
price). Sensitivity analyses were conducted to evaluate the robustness of the results 
and included a low- and high-cost scenario. RESULTS: Initial hospitalization costs 
were c1157 higher per patient receiving SES, driven primarily by the incremental 
acquisition cost for SES compared BMS. Follow-up direct costs were similar in both 
groups of patients, however the indirect costs in SES patients were signiﬁ cantly lower. 
Overall 36-month MACE-related costs were c283 not signiﬁ cantly higher in the SES 
group (p = 0.62). The ICER based on 2009 cost data resulted in c5320 per MACE 
avoided. Variation of incremental SES prices between c650 and c750 showed no 
signiﬁ cant impact. CONCLUSIONS: Incorporating updated cost data can drastically 
change the ICER generated from health services research projects. Modelling with 
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OBJECTIVES: NHS North Yorkshire and York commissioned York Health Econom-
ics Consortium to carry out an evaluation of their recent Telehealth pilot involving 
patients with long-term conditions. The ﬁ ndings from the evaluation will be used to 
inform plans for the further rollout of Telehealth in North Yorkshire. METHODS: 
Three approaches were employed: a questionnaire was used to obtain details about 
the Telehealth experiences of users and their carers; Case Managers and Community 
Matrons with Telehealth patients on their caseloads were interviewed about referral 
criteria and the impact of Telehealth on their role and patient care; Health care 
resource use data were analyzed. Some caution should be used when generalizing 
ﬁ ndings due to the small sample size and the speciﬁ c characteristics of pilot Telehealth 
recipients. RESULTS: Forty-eight questionnaires were handed out and twenty 
returned (42%). Overall, respondents were happy with Telehealth (90%). Results 
showed that the installation process had been smooth (75%); individuals had received 
sufﬁ cient tuition (95%); they were conﬁ dent using the equipment (95%); and were 
happy with the service received from the monitoring centre (95%). Telehealth gave 
users peace of mind and helped them to manage their own health condition. However, 
a number of users had experienced technical issues (during installation and when 
taking daily measurements). Although there had been some teething problems, mainly 
in relation to the installation process and the monitoring system, clinicians were 
broadly supportive of Telehealth. There was a repeated view that individual patient 
characteristics needed to be taken into account when identifying patients who would 
beneﬁ t from Telehealth. The impact of Telehealth on health care resource use was 
difﬁ cult to determine within the eight month timescale of the pilot. CONCLUSIONS: 
Telehealth gives users peace of mind and helps them manage their health; however, 
its impact on health care resource use is still unclear.
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OBJECTIVES: This analysis aims to explore management of acute coronary syn-
dromes (ACS) from acute event to hospital discharge in Austria, and to measure 
Quality of Life (QoL) at discharge. METHODS: This 12-month international, pro-
spective, observational study recruited ACS patients in selected hospitals undergoing 
percutaneous coronary intervention (PCI), April 2008–March 2009, capturing prac-
tice patterns, resource use and QoL. RESULTS: A total of 148 ACS-PCI patients (out 
of the 152 recruited) were eligible: median age 60 yrs (IQR 51–69), median weight 
80 kg (IQR 70–89), 20% female, 28% Type II diabetics, and 17% prior myocardial 
infarction (MI). Index diagnosis was: unstable angina or non-ST-elevation MI (UA/
NSTEMI)-44% and ST-elevation MI (STEMI)-56%. Almost all patients (96%) 
received stents: 28% bare metal stents only, 70% drug eluting stents only and 2% 
both. Time from start of ACS symptoms to PCI was ≤3 days in 86% of UA/NSTEMI 
patients and ≤1 day in 98% of STEMI patients. Oral antiplatelet medications with 
loading dose (LD) used: aspirin-97% and clopidogrel-91%. Clopidogrel LD was 
administered in the ambulance-9%, previous hospital-10%, emergency room-41%, 
CCU or ICU-31%, catheterization lab-5%, or other ward-5%. LD was administered 
between 6 hours before to 6 hours after PCI in 82% of cases. The ﬁ rst clopidogrel 
LD was 600 mg in 85% and 300 mg in 10% of cases and in-hospital maintenance 
dose was 75 mg in 97%. At time of hospital discharge, 97% of the discharged patients 
were prescribed clopidogrel (discharge dose 75 mg for all patients except one). QoL 
in discharged patients was good: median EQ-5D health state index at 1.00 (IQR 
0.81–1.00). CONCLUSIONS: These real life data reﬂ ect treatment patterns among 
ACS patients managed by PCI in selected hospitals in Austria in 2008–2009. Timing 
and place of loading of antiplatelet agents differ. The QoL of patients at discharge 
was high.
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OBJECTIVES: Current European Society of Cardiology Guidelines recommend dual 
antiplatelet therapy for 12 months for patients with acute coronary syndrome (ACS); 
however, reimbursement for antiplatelet therapy differs by EU country and is depen-
dent upon the use of bare metal (BMS) or drug-eluting (DES) stents during percutane-
ous coronary intervention (PCI). Dual antiplatelet (clopidogrel + aspirin) treatment 
